FCF Life Sciences
Venture Capital Monitor
-
Europe

The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.

FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

As of the end of April 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 3,421m so far
  • Top 5 Deals exceed EUR 70m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Two of the Top 5 Deals took place in Germany, Patient21 (EUR 125m) and Ada Health (EUR 106m)
  • Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • The Biotech sector received 43% of the total investment volume
  • Oncology still dominates the Biotechnology sector as top indication
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS